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Background. Chlamydia trachomatis genital tract infection is a major cause of female reproductive morbidity. Risk factors for
ascending infection are unknown, and the role for antibody in protection is not well established.
Methods. We recruited 225 women from urban outpatient clinics and followed them for a median of 12 months. We performed
a cross-sectional analysis of serum anti-chlamydial immunoglobulin G (IgG), behavioral factors, and microbiological factors asso-
ciated with endometrial infection at enrollment, and a longitudinal analysis of factors associated with incident infection.
Results. Oral contraceptives (adjusted relative risk [RR], 2.02 [95% confidence interval {CI}, 1.38–2.97]) and gonorrhea (adjusted
RR, 1.66 [95% CI, 1.07–2.60]) were associated with endometrial infection. Gonorrhea (adjusted hazard ratio [HR], 3.09 [95% CI,
1.41–6.78]), cervical infection at enrollment (adjusted HR, 2.33 [95% CI, 1.07–5.11]), and exposure to uncircumcised partners (ad-
justed HR, 2.65 [95% CI, 1.21–5.82]) or infected partners (adjusted HR, 4.99 [95% CI, 2.66–9.39]) significantly increased the risk of
incident infection. Seropositivity was associated with a reduced cervical burden (P < .05) but no differences in rates of ascending
infection (adjusted RR, 1.24 [95% CI, .71–2.19]) or incident infection (adjusted HR, 0.94 [95% CI, .52–1.69]).
Conclusions. Serum anti-chlamydial IgG is not associated with a lowered rate of ascending or repeat infection. Identification of
factors associated with ascending infection and increased risk of incident infection provide guidance for targeted screening of women
at increased risk for sequelae.
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Chlamydia trachomatis causes >100 million genital tract infec-
tions annually and remains a significant global health problem
[1]. In some infected women, C. trachomatis ascends to the upper
genital tract and leads to pelvic inflammatory disease (PID),
chronic pelvic pain, ectopic pregnancy, and tubal factor infertility
[2]. Multiple studies have revealed risks for incident infection in
women, including young age, minority race, gonorrhea, and new
or multiple sex partners [3–5].To our knowledge, no studies have
comprehensively examined risk factors for ascending infection.
Defining these could aid clinicians in providing targeted screen-
ing for women at greatest risk.
The role of antibody in response to C. trachomatis genital
tract infection remains unclear. Antibody is dispensable for
normal resolution of primary infection in the murine model
of chlamydial genital infection but contributes to resistance
from reinfection [6]. Data from mouse and guinea pig models
link serum anti-chlamydial immunoglobulin G (IgG) to reduced
bacterial load, duration of infection, and pathology [6, 7]. In con-
trast, data from human studies indicate minimal to no role for
serum antibody in resistance. Several studies correlated high titers
of serum anti-chlamydial IgG with increased morbidity [8–11],
while other studies described protective effects for IgG and im-
munoglobulin A (IgA) [12, 13]. In contrast, Cohen et al reported
that levels of IgG or IgA specific for chlamydial elementary bod-
ies (EBs) or heat shock protein 60 (HSP60) were not associated
with a decreased risk of infection [14]. IgG is the major antibody
subclass in genital secretions, where it predominates over IgA
[15]. Serum IgG transudates into cervical secretions, so levels of
IgG in serum and endocervical mucus are highly correlated [16].
Since IgG is the dominant antibody to C. trachomatis [17], the
role of IgG in protection from chlamydia requires clarification.
Our objectives were to define risk factors for ascending infec-
tion, confirm risk factors for incident infection, and determine
the relationship of serum anti-chlamydial IgG to bacterial bur-
den and to ascending and incident infection. We hypothesized
that although antibody would not associate with resistance to
reinfection, high titers would correlate with a reduced bacterial
burden.
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METHODS
Patient Population
The institutional review boards for human subject research at
the University of Pittsburgh and the University of North Caro-
lina approved the study. Women aged 15–35 years who had
lower genital tract infections or were at risk for chlamydia infec-
tion were approached for enrollment from February 2011
through May 2014. Women were recruited from the Allegheny
County Health Department’s Sexually Transmitted Diseases
Clinic, Magee-Womens Hospital (MWH) Ambulatory Care
Clinic, and the Reproductive Infectious Disease Research Unit
at MWH. Eligibility criteria were clinical evidence of mucopur-
ulent cervicitis, diagnosis of gonorrhea or chlamydia prior to
treatment, or reported sexual contact with a male who received
a diagnosis of gonorrhea, chlamydia, or nongonococcal urethri-
tis. Exclusion criteria included pregnancy, uterine procedure or
miscarriage in the preceding 60 days, menopause, hysterectomy,
antibiotic therapy in the preceding 14 days, and allergy to study
medications. Women with acute PID were excluded.
Subjects provided informed consent at the time of enrollment
and agreed to attend follow-up visits 1, 4, 8, and 12 months after
enrollment. At enrollment, study personnel obtained demograph-
ic data and a standardized medical history. Subjects completed a
questionnaire regarding behavioral practices, sex exposure, con-
traceptive methods, and symptoms. General physical and pelvic
examinations were performed; vaginal fluid was collected for
pH measurement, whiff testing for the presence of amines, and
microscopy to detect clue cells, as well as for subsequent diagnosis
of bacterial vaginosis by use of Amsel criteria [18]. Vaginal swab
specimens were collected for culture and molecular testing
for Trichomonas vaginalis (Aptima TV; Gen-Probe, San Diego,
California). Nucleic acid amplification tests (NAATs) were per-
formed on cervical swabs for detection ofC. trachomatis andNeis-
seria gonorrhoeae (Aptima Combo 2, Gen-Probe, San Diego,
California) and Mycoplasma genitalium (Aptima MG: Gen-
Probe, San Diego, California). Serum was collected for analysis
of anti-chlamydial antibody titers, human immunodeficiency
virus (HIV) antibody, and syphilis testing.
Women underwent endometrial sampling at enrollment. The
cervix was cleaned with Betadine, a sterile endometrial sampler
(Unimar Pipelle de Cornier, CooperSurgical, Shelton, Connect-
icut) was placed into the endometrial cavity, and a tissue sample
was aspirated into the cannula. The tissue specimen was dis-
charged into a sterile Petri dish. Tissue proximal to the sampling
portal of the cannula was placed in 10% formalin fixative, distal
tissue was used for microbiologic culture, and a swab absorbed
5 mm of distal tissue for qualitative NAAT (Aptima). All partic-
ipants received single-dose agents for gonorrhea (ceftriaxone,
125 mg intramuscularly), chlamydia (azithromycin, 1 g orally),
and bacterial vaginosis (metronidazole, 2 g orally).
At follow-up visits, subjects completed a questionnaire address-
ing symptomatology and interim medical and sexual history.
Vaginal fluid and vaginal and cervical swab specimens were col-
lected and analyzed as described above.
Serum Antibody Titers
Enrollment antibody titers were measured by a microimmuno-
fluorescence assay, performed at the University of Washington.
The assay identifies IgG and immunoglobulinM (IgM) antibodies
to chlamydial EBs from the 14 major serovars of C. trachomatis,
Chlamydia pneumoniae, and Chlamydia psittaci and detects chla-
mydia anti-lipopolysaccharide (genus-specific) and anti-major
outer membrane protein (MOMP; serovar-specific) antibodies
[19]. IgG titers of ≥1:16 were considered positive.
Cervical and Endometrial Bacterial Load
DNAwas extracted from 180 µL of the reserved cervical or endo-
metrial swab eluate to generate a template for the quantitation of
chlamydial burden. Genomic DNAwas extracted using a Quick-
DNA Universal Kit (Zymo Research, Irvine, California) accord-
ing to the manufacturer’s protocol. The abundance of chlamydial
DNA present in the extracted material was determined by quan-
titative PCR with SsoAdvanced SYBRmix (Bio-Rad) and primers
directed against chlamydial 16S ribosomal DNA, using a CFX
iCycler (Bio-Rad) [20]. Each specimen was assayed in triplicate.
Statistical Analysis
Risk factors for ascending infection were determined by log-
binomial regression of cross-sectional enrollment data [21]. Risk
factors for incident chlamydia infection were determined using
the Wei–Lin–Weissfeld method, a marginal Cox model account-
ing for multiple chlamydial infections per person that adjusts for
within-subject correlations [22]. Incident C. trachomatis infection
was defined as any C. trachomatis–positive test result during
follow-up, and the incidence rate was defined as the number of
incident infections per person-years at risk. Sociodemographic
factors analyzed as potential risk factors for incident infection
were determined at enrollment, whereas microbiologic, sexual his-
tory and exposure, and contraception data used for these analyses
were gathered at each follow-up visit. For ascending and incident
infection, we calculated the unadjusted relative risk (RR) and haz-
ard ratio (HR), using a univariable model that measured 1 inde-
pendent variable at a time. We then developed final multivariable
parsimonious regression models to determine the best subset of
risk factors for ascending and incident infection by stepwise
regression, with the α to enter set at P≤ .2 and the α to be main-
tained set at P≤ .1. We reported the adjusted RR or HR for var-
iables maintained in the final model. In a separate analysis,
independent variables that were tested but not retained in the
final models were adjusted for the variables that were retained.
To assess the relationship between IgG titer and chlamydial
burden, we log transformed the cervical and endometrial bur-
den data, performed Shapiro–Wilk normality tests to ensure
normal distribution, and compared chlamydial burdens of sero-
negative and seropositive women, using unpaired t tests. Linear
524 • JID 2016:213 (15 February) • Russell et al
regression assessed the dependence of the endometrial chla-
mydial burden on the cervical chlamydial burden.
We compared the frequency of clinical symptoms among
women with chlamydia infection to that among women with
sexually transmitted coinfections, using the Fisher exact test.
The frequency of incident infection among women infected at
enrollment was compared to that among uninfected women
with reported chlamydial exposure within 3 weeks of enrollment,
using the Fisher exact test. We used χ2 tests to compare the
frequency of seropositivity among women with cervix-only and
cervix plus endometrium infection and to compare the frequency
of cervical ectopy (encompassing ≥25% of the cervical face)
among oral contraceptive pill (OCP) users and non-OCP users.
Risk factor analyses were conducted using R (version 3.1.1).
Other tests were performed using GraphPad Prism, version 6.05
for Windows (GraphPad Software, La Jolla, California). P values
of <.05 were considered statistically significant.
RESULTS
Baseline Patient Characteristics
The data set included 225 women who attended 933 visits, with a
median follow-up of 12 months (interquartile range, 8–12
months). Within the cohort, 172 women (76%) completed at
least 3 follow-up visits, and 128 (57%) completed 4. There were
no sociodemographic differences between women who attended
all visits and those who did not (data not shown). Table 1 shows
demographic characteristics of the cohort. The cohort comprised
mainly young (median age 21 years; range, 18–35 years), single
(89%), African American (66%) women who were enrolled
from ambulatory clinics. The majority (55%) reported having
previously received a diagnosis of chlamydia, and 24% re-
ported having had ≥2 prior infections. Subjects commonly
reported past infections with N. gonorrhoeae (21%) and/or
T. vaginalis (28%). Two-thirds of women (67%) reported a
past history of at least 1 bacterial STI. There were no reports
of HIV infection, and reports of genital herpes (8%) and gen-
ital warts (6%) were uncommon.
The cohort was sexually active, reporting prior pregnancy
(55%), a miscarriage or abortion (33%), an ectopic pregnancy
(5%), and a prior PID (10%). Eighty-seven percent reported
sex with a male within 30 days preceding enrollment, and
20% reported multiple male partners during this period.
Many women (42%) reported having had sex in the preceding
3 months with a male who had a sexually transmitted infection.
Thirty (13%) reported an untreated chlamydia diagnosis within
3 weeks of enrollment; none reported a gonorrhea diagnosis
during this period. Although 58% reported condom use prior
to enrollment, only 12% reported use 100% of the time. Twelve
percent reported using combined OCPs, and none reported
using progestin-only pills, but women receiving OCPs did not
have a higher frequency of cervical ectopy on examination,
compared with non-OCP users (P = .15).
Many women in the cohort were asymptomatic. Of 149
women with chlamydia at enrollment, vaginal discharge and
urinary symptoms were reported in 38% and 21%, respectively.
Pelvic examination revealed moderate-to-profuse vaginal or
cervical discharge in 57% and 44%, respectively. Twenty-three
women (15%) were coinfected with M. genitalium, and 15
(10%) were coinfected with N. gonorrhoeae; 3 subjects were in-
fected with all 3 pathogens at enrollment. Women with chla-
mydia and M. genitalium coinfection were more likely to
report dysuria than those with chlamydia infection alone
(17.4% vs 3.7%; P = .03); otherwise, symptoms and signs were
not higher in women with coinfections (data not shown). At
the 1-month visit, C. trachomatis was redetected in 6% of
women, which could represent treatment failure or repeat
infection.
Factors Associated With the Presence of Endometrial Infection
Of 149 women with cervical chlamydial infection, 63 (42%) also
had chlamydiae detected in the swab of their endometrial biop-
sy specimen. Factors associated with ascending infection are re-
ported in Table 2. Sex with a new partner in the preceding 30
days (RR, 1.62 [95% CI, 1.13–2.33]), sex during previous men-
strual period (RR, 1.69 [95% CI, 1.12–2.57]), and OCP use (RR,
Table 1. Baseline Sociodemographic Characteristics for Cohort of Highly
Exposed Women in Pittsburgh, Pennsylvania
Characteristic Value (n = 225)
Age, y, median (range) 21 (18–35)
Race/ethnicity
African American 148 (66)
White 48 (21)
Hispanic or Latino 13 (6)
Multiracial 23 (10)
Other 6 (3)
Marital status
Married 1 (0.4)
Living with partner for ≥4 mo 21 (9)
Divorced or separated 3 (1)
Single 200 (89)
Education level
Less than high school graduate 36 (16)
High school graduate or GED degree 82 (36)
Vocational training 15 (7)
Some college work 73 (32)
College graduate 19 (8)
Insurance
Private 57 (25)
Medicaid 105 (47)
Other 8 (4)
None 55 (24)
Substance use
Smoking 114 (51)
Marijuana use 85 (38)
Alcohol use 114 (51)
Data are no. (%) of subjects, unless otherwise indicated.
Abbreviation: GED, general education development.
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2.02 [95% CI, 1.43–2.84]) were significantly associated with an
increased risk of ascension in this unadjusted analysis. Stepwise
regression identified 3 variables (exposure to a new partner in the
preceding 30 days, OCP use, and gonorrhea) that met criteria for
retention in the final multivariable model. After adjusting for
these variables, OCP use (adjusted RR, 2.02 [95% CI, 1.38–2.97)
and gonorrhea (adjusted RR, 1.66 [95% CI, 1.07–2.60]) remained
significantly associated with ascending infection, but sex with a
new partner was no longer significant (adjusted RR, 1.36 [95%
CI, .96–1.92]). Four additional variables (exposure to multiple
partners, sex with an uncircumcised male, sex during a previous
menstrual period, and historical chlamydia infection) were tested
but not maintained, and none were significant after adjustment for
retained variables. Age, race, and marital status were not associated
with an altered rate of endometrial infection (not shown).
Risk Factors for Incident Infection During Follow-up
During 2058 person-months of risk, 48 women (21.3%) were
positive for C. trachomatis, and the incidence rate was 28
cases per 100 person-years (95% CI, 22–36 cases per 100 per-
son-years). Our univariable analysis indicated that older age
(HR, 0.87 [95% CI, .78–.97]) was associated with a reduced rate
of incident infection (Table 3). Race, ethnicity, and marital status
were not associated with an altered rate of incident infection (data
not shown), but there was a trend toward a reduced risk with in-
creasing education level. Detection of gonorrhea at any follow-up
visit was associated with increased incident chlamydia rates (HR,
3.99 [95% CI, 2.22–7.15]), but neither M. genitalium infection,
T. vaginalis infection, nor bacterial vaginosis significantly in-
creased the risk of incident chlamydial infection. Exposure to a
partner with a sexually transmitted infection (HR, 3.76 [95%
CI, 2.21–6.41]) or C. trachomatis infection (HR, 5.07 [95% CI,
3.01–8.53]), ≥3 partners (HR, 5.38 [95% CI, 1.22–23.76]), new
partners (HR, 1.74 [95% CI, 1.10–2.76]), and uncircumcised
partners (HR, 3.17 [95% CI, 1.68–5.98]) were associated with
increased rates of incident chlamydia. Women reporting depot
medroxyprogesterone (DMPA) injection receipt (HR, 1.80 [95%
CI, 1.08–3.01]), coitus interruptus (HR, 1.89 [95% CI, 1.14–3.12]),
or condom use (HR, 1.67 [95% CI, 1.04–2.70]) were at signifi-
cantly increased risk of infection.
Six factors were retained in our final multivariable model:
age, gonorrhea, chlamydia infection at enrollment, and sex
Table 2. Factors Associated With Endometrial Chlamydia trachomatis Infection at Enrollment
Factor
Site of Infection, No. (%) Univariable Analysis Multivariable Model
Cervical
Infection (n = 86a)
Endometrial
Infection (n = 63a)
Unadjusted RR
(95% CI)b P Value
Adjusted RR
(95% CI)c P Value
At enrollment
Neisseria gonorrhoeae infection 9 (10) 11 (16) 1.34 (.86–2.09) .19 1.66 (1.07–2.60)d .03
Mycoplasma genitalium infection 17 (22) 9 (15) 0.76 (.43–1.34) .34 NA NA
Trichomonas vaginalis infection 14 (21) 9 (18) 0.90 (.51–1.57) .70 NA NA
Bacterial vaginosis 21 (26) 16 (26) 1.02 (.66–1.57) .93 NA NA
Before enrollment
C. trachomatis infection 53 (62) 30 (48) 0.72 (.50–1.05) .09 0.76 (.51–1.13)e .17
Sexual activity
≥2 partners in prior 30 d 13 (15) 15 (24) 1.35 (.90–2.03) .15 0.91 (.57–1.48)e .72
New partner in prior 30 d 15 (17) 22 (35) 1.62 (1.13–2.33) .01 1.36 (.96–1.92)d .08
New partner in prior 12 mo 55 (64) 45 (71) 1.23 (.80–1.88) .35
Uncircumcised partner in prior 3 mo 3 (4) 5 (8) 1.53 (.86–2.71) .15 0.80 (.40–1.61)e .53
Sex during last menstrual period 4 (5) 9 (14) 1.69 (1.12–2.57) .01 1.17 (.78–1.76)e .45
Contraception (At enrollment)
OCPs 4 (5) 13 (21) 2.02 (1.43–2.84) <.01 2.02 (1.38–2.97)d .0003
DMPA 13 (15) 9 (14) 0.96 (.56–1.65) .89 NA NA
Intrauterine device 11 (13) 9 (14) 1.08 (.64–1.82) .79 NA NA
Condoms 49 (57) 35 (56) 0.97 (.66–1.41) .86 NA NA
Coitus interruptus 33 (38) 22 (35) 0.92 (.62–1.36) .67 NA NA
Abstinence 9 (10) 7 (11) 1.04 (.58–1.88) .90 NA NA
None 13 (15) 8 (13) 0.89 (.50–1.58) .68 NA NA
Abbreviations: CI, confidence interval; DMPA, depot medroxyprogesterone; NA, not applicable; OCP, oral contraceptive pills; RR, relative risk.
a Data are for women who reported or had the factor.
b Data were determined by log binomial regression. Unless otherwise indicated, reference groups are composed of all women who did not report or have the specified factor.
c Any independent variable with an unadjusted P value of ≤.2 was tested in a final multivariable model, using stepwise regression, and variables with a P value of≤.1 were maintained. No
adjusted RR is provided for variables that were not tested in the model, as indicated by “NA.” Unless otherwise indicated, reference groups are composed of all women who did not report or
have the specified factor.
d Variable was maintained in the final multivariable model.
e Variable was tested but not maintained in the final multivariable model.
526 • JID 2016:213 (15 February) • Russell et al
with new, uncircumcised, or infected partners. After adjustment
for these variables, gonorrhea (adjusted HR, 3.09 [95% CI,
1.41–6.78]), sex with an infected partner (adjusted HR, 4.99
[95% CI, 2.66–9.39]), sex with an uncircumcised male (adjusted
HR, 2.65 [95% CI, 1.21–5.82]), and cervical chlamydial infec-
tion at enrollment (adjusted HR, 2.33 [95% CI, 1.07–5.11])
Table 3. Risk Factors for Incident Chlamydia trachomatis Infection
Risk Factor
Univariable Analysis Multivariable Model
Unadjusted HR (95% CI)a P Value Adjusted HR (95% CI)b P Value
Age, y 0.87 (.78–.97) .01 0.92 (.84–1.00)c .06
Education level
Less than high school graduate Reference . . . Reference . . .
High school graduate or GED degree 0.66 (.39–1.14) .14 0.85 (.46–1.56)d .60
Vocational training 1.52 (.69–3.33) .30 1.73 (.89–3.38)d .11
Some college education 0.56 (.30–1.05) .07 0.93 (.47–1.83)d .84
College graduate 0.24 (.06–1.01) .05 0.50 (.11–2.16)d .35
Substance use
Smoking 1.13 (.71–1.78) .61 NA NA
Marijuana use 1.32 (.84–2.06) .23 NA NA
Alcohol use 0.83 (.52–1.30) .41 NA NA
Infection type during follow-up
N. gonorrhoeae infection 3.99 (2.22–7.15) <.0001 3.09 (1.41–6.78)c .005
M. genitalium infection 1.48 (.80–2.72) .21 NA NA
T. vaginalis infection 1.16 (.51–2.66) .72 NA NA
Bacterial vaginosis 1.36 (.57–3.23) .49 NA NA
Site of C. trachomatis infection at enrollment
Uninfected Reference . . . Reference . . .
Cervix only 3.14 (1.56–6.33) .001 2.33 (1.07–5.11)c .03
Cervix/endometrium 2.10 (.98–4.53) .06 1.54 (.66–3.59)c .32
STI diagnosis received by partner during follow-up
C. trachomatis infection, N. gonorrhoeae infection,
or nongonococcal urethritis
3.76 (2.21–6.41) <.0001 0.94 (.30–2.98)d .91
C. trachomatis infection 5.07 (3.01–8.53) <.0001 4.99 (2.66–9.39)c <.0001
N. gonorrhoeae infection 2.16 (.50–9.34) .30 NA NA
Sex exposure
Male partner(s) since last visit, no.
0 Reference . . . Reference . . .
1 2.24 (.51–9.74) .28 1.69 (.38–7.50)d .49
2 4.10 (.94–17.86) .06 1.99 (.41–9.65)d .39
≥3 5.38 (1.22–23.76) .03 2.86 (.61–13.42)d .18
New male partner(s) since last visit, no.
0 Reference . . . Reference . . .
≥1 1.74 (1.10–2.76) .02 1.56 (.95–2.57)c .08
Sex with uncircumcised male in last 3 mo 3.17 (1.68–5.98) .0004 2.65 (1.21–5.82)c .02
Sex during last menstrual period 0.99 (.47–2.07) .98 NA NA
Contraception (Reported at any visit)
OCPs 0.75 (.40–1.38) .35 NA NA
DMPA 1.80 (1.08–3.01) .02 1.03 (.59–1.78)d .92
Condoms 1.67 (1.04–2.70) .04 1.39 (.79–2.45)d .26
Coitus interruptus 1.89 (1.14–3.12) .01 1.52 (.89–2.59)d .13
Abstinence 0.36 (.09–1.53) .17 NA NA
None 1.05 (.53–2.04) .90 NA NA
Cervical ectopy 0.78 (.49–1.23) .29 NA NA
Abbreviations: CI, confidence interval; DMPA, depot medroxyprogesterone; GED, general education development; HR, hazard ratio; NA, not applicable;M. genitalium,Mycoplasma genitalium;
N. gonorrhoeae, Neisseria gonorrhoeae; OCP, oral contraceptive pills; STI, sexually transmitted infection; T. vaginalis, Trichomonas vaginalis.
a Analysis was performed using the Wei–Lin–Weissfeld method, which is a marginal Cox model for repeated data. Unless otherwise indicated, reference groups are composed of all women
who did not report or have the specified factor.
b Any independent variable with an unadjusted P value of ≤.2 was tested in a final multivariable model, using the stepwise regression, and variables with a P value of≤.1 were maintained. No
adjusted HR is provided for variables that were not tested in the model, as indicated by “NA.” Unless otherwise indicated, reference groups are composed of all women who did not report or
have the specified factor.
c Variable was maintained in the final multivariable model.
d Variable was tested but not maintained in the final multivariable model.
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remained significant risk factors for incident infection. Table 3
shows the adjusted HR for tested variables not retained in the
multivariable model; none remained a significant risk factor
after adjustment for maintained variables.
Unadjusted analyses revealed that women infected at enroll-
ment had an increased risk of incident infection, compared with
uninfected women, regardless of infection site (HR, 3.14 [95%
CI, 1.56–6.33] for the cervix and 2.10 [95% CI, .98–4.53] for the
cervix/endometrium). The risk of incident infection was lower
for women with endometrium infection, compared with those
with cervix-only infection, although nonsignificantly so (HR,
0.67 [95% CI, .41–1.10]; P = .10). After adjustment for the
variables in the final model, only cervical infection increased
the risk of incident infection (adjusted HR, 2.33 [95% CI,
1.07–5.11]).
Of 49 (65%) women reporting exposure to an infected part-
ner within 3 months of enrollment, 46 (94%) denied receiving
treatment, suggesting that they either resisted infection or
became infected and experienced spontaneous clearance of
infection. Only 11% of these women became infected during
follow-up, compared with 36% of those infected at enrollment
(P = .0008). Thus, women who resisted infection or resolved in-
fection spontaneously exhibited a reduced risk of incident infec-
tion, as described by Geisler et al [23].
Relationship of Anti-chlamydial Antibody Titers at Enrollment to
Ascending and Incident Infection
Sixteen percent of subjects were seronegative and 83% were se-
ropositive at enrollment. Nineteen (46%) of 35 women who de-
nied prior infection and were uninfected at enrollment had
titers of 1:16–1:8192, indicating that they had resolved an unde-
tected infection. The frequency of seropositivity was similar for
women with cervical and endometrial infection (P = .48). Sero-
positivity was not associated with a reduced risk of ascending
(adjusted RR, 1.24 [95% CI, .71–2.19]) or incident infection
(adjusted HR, 0.94 [95% CI, .52–1.69]) after adjustment for
risk factors included in the final multivariable models (Table 4).
Relationship of Anti-chlamydial Antibody Titers at Enrollment to Upper
and Lower Tract Chlamydial Burden
Seropositive women with midrange (1:16–1:256) and high
(1:512–1:8192) titers of anti-chlamydial serum IgG had lower
bacterial burdens in cervical swab specimens, compared with
seronegative women (Figure 1A; seronegative vs titers of 1:16–
1:256, P < .005; seronegative vs titers of 1:512–1:8192, P = .01).
There was no difference in endometrial chlamydial burden be-
tween seronegative and seropositive women (Figure 1B; sero-
negative vs titers of 1:16–1:256, P = .85; seronegative vs titers
of 1:512–1:8192; P = .86). Linear regression did not reveal a stat-
istically significant interaction between the endometrial and
cervical burdens (P = .17; Figure 1C).
DISCUSSION
Long-term sequelae caused by C. trachomatis infection in
women occur because it ascends from the cervix to the upper
genital tract. Our recruitment of women with likely or known
exposure to C. trachomatis led to the inclusion of a high fre-
quency of women (66%) with active infection. We determined
that OCP use and coinfection with N. gonorrhoeae were associ-
ated with an increased rate of endometrial infection. Risk fac-
tors for incident infection included the presence of infection
limited to the cervix at the time of enrollment, gonorrhea at
any follow-up visit, sex with a partner who received a diagnosis
of chlamydia at any time during follow-up, and sex with an un-
circumcised male in the previous 3 months.
We found a highly significantly increased risk of ascending
infection in women using OCPs, but DMPA use was not asso-
ciated with endometrial infection. In guinea pigs, treatment
with estrogen [24] or estrogen and progesterone [25] leads to in-
creased ascension and upper genital tract pathology. Addition-
ally, in vitro studies have shown that estrogen increases
chlamydial attachment to human endometrial epithelial cells
[26]; this is one potential mechanism for increased ascension
in OCP users. In a secondary analysis of a cohort of patients
with PID treated in the United States during the 1980s, OCPs
Table 4. Relationship of Serum Anti-Chlamydia trachomatis Immunoglobulin G (IgG) Titer to Ascending Infection at Enrollment and Incident Infection Over
1 Year of Follow-up
IgG Titer
Ascending Infection at Enrollment Incident Infection During Follow-up
Unadjusted
RR (95% CI)a P Value
Adjusted RR
(95% CI)b P Value
Unadjusted HR
(95% CI)c P Value
Adjusted HR
(95% CI)d P Value
≤1:8 Reference . . . Reference . . . Reference . . . Reference . . .
1:16–1:8192 0.29 (.47–1.26) .77 1.24 (.71–2.19) .45 1.19 (.58–2.46) .63 0.94 (.52–1.69) .82
Abbreviations: CI, confidence interval; HR, hazard ratio; RR, relative risk.
a Data were determined by log binomial logistic regression.
b Analysis adjusted for the 3 variables included in our final multivariate model for ascending infection: Neisseria gonorrhoeae coinfection, sex with new male partners, and oral contraceptive pill
use.
c Analysis was performed using the Wei–Lin–Weissfeld method, which is a marginal Cox model for repeated data.
d Analysis adjusted for the 6 variables included in final multivariate model for incident infection over time: age, Neisseria gonorrhoeae infection, C. trachomatis infection at enrollment, exposure
to a partner with C. trachomatis, sex with a new partner, and sex with an uncircumcised male.
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were not associated with upper genital tract chlamydial infec-
tion [27]. Our study excluded women with symptomatic PID.
Although OCP use may increase ascension, other factors may
be more important in determining the development of PID
symptoms.
N. gonorrhoeae coinfection also significantly increased the
risk of endometrial infection in our final multivariable model,
suggesting that N. gonorrhoeaemay impair the host immune re-
sponse to C. trachomatis. Neutrophils elicited in response to
gonorrhea may lead to enhanced sloughing of chlamydia-
infected epithelial cells and promote ascension [28]. As another
possible mechanism for this effect, N. gonorrhoeae can inhibit
proliferation and expansion of antigen-specific CD4+ T cells
through effects on host antigen-presenting cells [29].
Recent cohort studies by Hwang et al and Aghaizue et al ex-
amined risk factors for incident chlamydial infection in young
women and reported infection rates of 4% and 4.9%, respective-
ly, at enrollment and incident infection rates of 15% and 5.7%,
respectively [4, 5]. Our recruitment strategy resulted in higher
rates of infection at enrollment (66%) and incident infection
during follow-up (28%), reflecting ongoing exposure among
our cohort. This allowed us to confirm reported risk factors
for incident infection, including young age, gonorrhea, expo-
sure to a partner with urethritis, and sex with new or multiple
partners [3–5]. Consistent with prior studies, we found a statis-
tical trend toward a reduction of risk with increasing education
level [30, 31]. Most of our cohort (71%) was African American,
and we were unable to reaffirm the reported increased risk
Figure 1. Comparison of serum anti-Chlamydia trachomatis immunoglobulin G (IgG) titer at enrollment to cervical (A) and endometrial (B) bacterial burden and relationship
between endometrial and cervical bacterial burden (C). A, Cervical bacterial burden measured by quantitative polymerase chain reaction (qPCR) performed on eluates of cervical
swab specimens obtained from women with infection at enrollment. Subjects were categorized as seronegative (titer ≤1:8; black circles) or seropositive with midrange titers
(1:16 to 1:256; white circles) or high titers (1:512 to 1:8192; squares) of anti-C. trachomatis IgG, based on enrollment titers measured by a microimmunofluorescence (MIF)
assay. Compared with seronegative women, seropositive women with midrange titers (P = .003, by the t test) and high titers (P = .01, by the t test) had a significantly lower
bacterial burden in the cervix. B, Endometrial bacterial burden measured by qPCR on eluates of swabs of biopsied tissue specimens obtained from all women with endometrial
infection at enrollment. Subjects were categorized as seronegative (titer ≤1:8; black circles) or seropositive with midrange titers (1:16 to 1:256; white circles) or high titers
(1:512 to 1:8192; squares) of anti-C. trachomatis IgG, based on enrollment titers measured by a MIF assay. There was no difference in upper genital tract burden among
seronegative and seropositive women with midrange titers (P = .85, by the t test) or high titers (P = .86, by the t test) of serum IgG. C, Linear regression of endometrial bacterial
burden and cervical bacterial burden of all women with endometrial infection at enrollment. The linear regression equation was as follows: y = 0.1224x + 2.906 (P = .17).
Abbreviation: rDNA, ribosomal DNA.
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among minority races [3, 4]. Hwang et al and Aghaizu et al ob-
served that smoking significantly increased the risk of incident
infection; we found a nonsignificantly increased risk in smokers
among our smaller cohort [4, 5].
DMPA use has recently been reported as a risk factor for HIV
infection [32–34]. Animal models of simian immunodeficiency
virus reveal that progesterone treatment depresses cellular im-
munity and causes thinning of lower genital tract epithelium,
increasing pathogen uptake [35, 36]. In our univariable analysis,
we found that DMPA increased the risk of incident chlamydial
infection, which is consistent with prior studies [37–39]. How-
ever, after adjustment for age and other variables maintained in
the model, DMPA was no longer significantly associated with
incident infection.
Women who were uninfected at enrollment (n = 76) had the
lowest risk of incident infection.Most (74%) were seropositive, in-
dicating past exposure, and 65% reported exposure to an infected
partner within 3 months of enrollment. Women with cervical in-
fection at enrollment had an increased risk of incident infection,
compared with these uninfected women. However, women with
cervical and endometrial infection did not. All women enrolled in
the study received antibiotics. Presumably, women with endome-
trium infection at enrollment were treated later in their infection
course than women presenting with infection in the cervix only,
allowing the host immune system adequate time to develop an
adaptive response that provided protection over the subsequent
year. These data support the “arrested immunity hypothesis” pro-
posed by Brunham et al in response to increasing rates of reinfec-
tion in areas where screening and treatment programs have been
instituted [40].
Our second objective was to investigate the role of serum an-
tibody in the host immune response to chlamydia. We found
that anti-chlamydial serum IgG titers were similar for women
with infection limited to the cervix and those with endometri-
um infection. This is consistent with the report by Miettinen
et al, who found no correlation between serum IgG or IgA to
MOMP and tissue site of chlamydial isolation in a small cohort
of patients with acute PID [41]. Furthermore, we did not find an
association between antibody and protection from ascending or
incident infection. This confirms prior work by Cohen et al that
showed no association between anti-chlamydial EB or anti-
chlamydial HSP60 serum IgG and the risk of incident infection
among female sex workers [14]. We found that seropositivity
was associated with reduced bacterial burden at the cervix but
not at the endometrium. Whether serum IgG plays a direct role
in reducing cervical bacterial burden or serves as a surrogate
marker for an alternate adaptive immune response remains
unclear.
A weakness of our study includes the potential overestima-
tion of the rate of incident infection, since we were unable to
distinguish treatment failure from reinfection in 11 women in-
fected at sequential visits. Analysis of the role of antibody in
protection would be improved by neutralization studies using
relevant human cells and sera from women with documented
resistance to reinfection. Last, use of NAAT to estimate the chla-
mydial burden may be less meaningful than quantitative cell
culture that enumerates live bacteria. Strengths of our study in-
clude recruitment of high-risk but otherwise normal healthy
young women, a high rate of follow-up, and extensive data on
sexual exposure, enabling adjustment for this important con-
founder. Infection of the upper genital tract is likely required
for induction of infertility. Repeated chlamydial infection has
been associated with an increased risk of long-term sequelae.
Thus, a determination of factors associated with endometrial
infection and repeat infection may aid in identification of
factors that increase a woman’s risk for tubal disease.
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